Filing Details
- Accession Number:
- 0000919574-23-004847
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-14 20:51:53
- Reporting Period:
- 2023-08-10
- Accepted Time:
- 2023-08-14 20:51:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1860782 | 2Seventy Bio Inc. | TSVT | Pharmaceutical Preparations (2834) | 863658454 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1907884 | Kynam Capital Management, Lp | 221 Elm Road Princeton NJ 08540 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2023-08-10 | 179,000 | $5.94 | 5,703,825 | No | 4 | P | Indirect | See Footnote |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2023-08-10 | 50,000 | $5.80 | 5,753,825 | No | 4 | P | Indirect | See Footnote |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2023-08-10 | 100,000 | $5.85 | 5,853,825 | No | 4 | P | Indirect | See Footnote |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2023-08-10 | 100,000 | $5.96 | 5,953,825 | No | 4 | P | Indirect | See Footnote |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2023-08-10 | 86,414 | $5.96 | 5,142,111 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2023-08-10 | 86,414 | $5.96 | 5,142,111 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Direct | |
No | 4 | P | Indirect | See Footnote |
Footnotes
- The reported securities are owned directly by Kynam Global Healthcare Master Fund, LP (the "Master Fund"), a private investment fund managed by Kynam Capital Management, LP (the "Adviser"), and separately managed account clients of the Adviser and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Kynam Capital Management GP, LLC (the "Adviser GP"), the general partner of the Adviser and (iii) Yue Tang, the managing member of the Adviser GP. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- The reported securities are directly owned by the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- The reported securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by Kynam Fund GP, LLC, the general partner of the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.